A multicenter randomized controlled clinical trial confirms that both chemical-first and electrical-first approaches are effective strategies for acute atrial fibrillation; however, an ...

Recent-onset atrial fibrillation, defined as an onset within one week, is a major issue in clinical practice, and recent advances have shown that cardioversion to normal sinus rhythm provides better ...

A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...

Demonstrating one potential application of the technology, an automated algorithm tied to the KardiaBand wearable ECG (AliveCor) performed “reasonably well” at detecting A-fib in patients scheduled ...

A 2015 high-quality meta-analysis used data from 15 studies with a total of 8,872 patients undergoing catheter ablation or cardioversion and receiving rivaroxaban or a vitamin K antagonist. There were ...

ROME -- Edoxaban (Savaysa) appears at least as safe as the standard warfarin (Coumadin)/enoxaparin (Lovenox) strategy for use in bridging anticoagulation around cardioversion for recent onset atrial ...

Pharmacological- and electrical-first cardioversion worked similarly well for treating acute atrial fibrillation (Afib) in the emergency department, according to the Canadian RAFF2 trial. The 204 ...

Bayer announced today the initiation of a global Phase II clinical trial (NCT07625215) evaluating BAY 3670549, an investigational highly selective G-protein-coupled inwardly rectifying potassium ...

If you have atrial fibrillation (AFib), you may not need any treatment, or you may be able to manage it with medication. But this condition is almost always progressive and often needs lifelong ...

A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...